Evidence map›Paper›PMID 27660167›Full record

SynthesisBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2016

Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.

Mohamed A Kharfan-Dabaja, Ambuj Kumar, Mehdi Hamadani, Stephan Stilgenbauer, Paolo Ghia, Claudio Anasetti, Peter Dreger, Emili Montserrat, Miguel-Angel Perales, Edwin P Alyea and 18 more

Open access · greenAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 2 pooled it
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 107 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Treatment of Richter's Transformation with Novel Therapies.Current hematologic malignancy reports · 2024
    Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Richter's Transformation.Current oncology reports · 2022
    Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 20 institutions in 7 countries.

Mohamed A Kharfan-DabajaDepartment of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center, Tampa, Florida; Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, Florida. Electronic address: Mohamed.Kharfan-Dabaja@Moffitt.org.
Ambuj KumarProgram for Comparative Effectiveness Research, University of South Florida College of Medicine, Tampa, Florida.
Mehdi HamadaniDivision of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Stephan StilgenbauerInternal Medicine III, Ulm University, Ulm, Germany.
Paolo GhiaDepartment of Onco-Haematology and Division of Experimental Oncology, IRCCS San Raffaele Hospital and Università Vita-Salute San Raffaele, Milan, Italy.
Claudio AnasettiDepartment of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center, Tampa, Florida; Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, Florida.
Peter DregerDepartment of Medicine V, University of Heidelberg, Heidelberg, Germany.
Emili MontserratDepartment of Hematology, Hospital Clínic, University of Barcelona, Barcelona, Spain.
Miguel-Angel PeralesAdult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Edwin P AlyeaMedical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Farrukh T AwanDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Ernesto AyalaDepartment of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center, Tampa, Florida; Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, Florida.
Jacqueline C BarrientosCLL Research and Treatment Program, Hofstra Northwell School of Medicine, New Hyde Park, New York.
Jennifer R BrownMedical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Januario E CastroUniversity of California San Diego, Moores Cancer Center, La Jolla, California.
Richard R FurmanDivision of Hematology-Oncology, Weill Cornell Medical College, New York, New York.
John GribbenJohn Vane Cancer Centre, Charterhouse Square, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
Brian T HillDepartment of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
Mohamad MohtyDepartment of Haematology, Saint Antoine Hospital, University Pierre & Marie Curie, and Inserm UMRs938, Paris, France.
Carol MorenoHospital de la Santa Creu Sant Pau, Barcelona, Spain.
Susan O'BrienThe University of California Irvine Chao Family Comprehensive Cancer Center, Orange, California.
Steven Z PavleticNational Institutes of Health-National Cancer Institute Experimental Transplantation and Immunology Branch, Bethesda, Maryland.
Javier Pinilla-IbarzDepartment of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, Florida; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, Florida.
Nishitha M ReddyDepartment of Medicine, Division of Hematology/Oncology, Vanderbilt University School of Medicine, Nashville, Tennessee.
Mohamed SorrorDepartment of Medicine, University of Washington School of Medicine and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Christopher BredesonThe Ottawa Hospital Blood and Marrow Transplant Program and the Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Paul CarpenterDepartment of Medicine, University of Washington School of Medicine and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Bipin N SavaniDepartment of Medicine, Division of Hematology/Oncology, Vanderbilt University School of Medicine, Nashville, Tennessee.
University of South Florida · USDana-Farber Cancer Institute · USUniversity of Washington · USVanderbilt University · USCleveland Clinic · USCornell University · USHeidelberg University · DEHofstra University · USHospital de Sant Pau · ESInserm · FRMedical College of Wisconsin · USMemorial Sloan Kettering Cancer Center · USNational Institutes of Health · USOttawa Hospital · CAQueen Mary University of London · GBThe Ohio State University · USUniversitat de Barcelona · ESUniversität Ulm · DEUniversity of California, Irvine · USUniversity of California San Diego · US

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
Tissue CoreP01CA081534 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KIPPS, THOMAS J · 2000 to 2016
$59.5M
NCI NIH HHS P01 CA081534NCI NIH HHS U24 CA076518
6 · The paper itself

Abstract

We sought to establish clinical practice recommendations to redefine the role of allogeneic hematopoietic cell transplantation (allo-HCT) for patients with chronic lymphocytic leukemia (CLL) in an era of highly active targeted therapies. We performed a systematic review to identify prospective randomized controlled trials comparing allo-HCT against novel therapies for treatment of CLL at various disease stages. In the absence of such data, we invited physicians with expertise in allo-HCT and/or CLL to participate in developing these recommendations. We followed the Grading of Recommendations Assessment, Development and Evaluation methodology. For standard-risk CLL we recommend allo-HCT in the absence of response or if there is evidence of disease progression after B cell receptor (BCR) inhibitors. For high-risk CLL an allo-HCT is recommended after failing 2 lines of therapy and showing an objective response to BCR inhibitors or to a clinical trial. It is also recommended for patients who fail to show an objective response or progress after BCR inhibitors and receive BCL-2 inhibitors, regardless of whether an objective response is achieved. For Richter transformation, we recommend allo-HCT upon demonstration of an objective response to anthracycline-based chemotherapy. A reduced-intensity conditioning regimen is recommended whenever indicated. These recommendations highlight the rapidly changing treatment landscape of CLL. Newer therapies have disrupted prior paradigms, and allo-HCT is now relegated to later stages of relapsed or refractory CLL.

Indexed as

Practice Guidelines as TopicAntineoplastic AgentsChildChild, PreschoolHematopoietic Stem Cell TransplantationHumansLeukemia, Lymphocytic, Chronic, B-CellSalvage TherapyTransplantation ConditioningTransplantation, HomologousAntineoplastic AgentsAllogeneic hematopoietic cell transplantationBCL-2 inhibitorsBCR inhibitorsChronic lymphocytic leukemia

Identifiers

PMID27660167
PMCPMC5116249
OpenAlexW2467680685

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.